Dysmenorrhea Treatment Market Research Report - Global Forecast till 2027

Dysmenorrhea Treatment Market Research Report: By Type (Primary Dysmenorrhea and Secondary Dysmenorrhea), Type of Treatment (Pain Relievers, Hormonal Therapy and Surgery) End User (Hospitals & Clinics, Research Centers and others) and Region (the Americas, Europe, Asia-Pacific and Middle East & Africa) - Global Forecast till 2027

ID: MRFR/Pharma/0256-HCR | February 2021 | Region: Global | 110 pages

Market Scenario


Dysmenorrhea Treatment Market is expected to exhibit significant growth over the forecast period. The market was valued at approximately USD 7,450 Million in 2018 and is projected to register a 12% CAGR over the forecast period.


Dysmenorrhea can be defined by painful, cramping, or throbbing sensations that occur before and during a menstrual period. It is also commonly called as menstrual cramps. Factors such as the growing prevalence of dysmenorrhea and increasing awareness and concern regarding the severity and therapeutics related to dysmenorrhea are expected to drive the market growth.


However, the probable side effects of the drugs are expected to hamper the market growth. 


Segmentation


The Global Dysmenorrhea Treatment Market has been segmented into type, type of treatment, end user, and region.


Based on type, the Global Dysmenorrhea Treatment Market has been segmented into primary dysmenorrhea and secondary dysmenorrhea.


The global dysmenorrhea treatment market, by type of treatment, has been divided into pain relievers, hormonal therapy, and surgery.


The global dysmenorrhea treatment market, by end user, has been classified as hospitals & clinics, research centers, and others.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The dysmenorrhea treatment market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.


The European dysmenorrhea treatment market has been segmented into Western Europe and Eastern Europe. The market in Western Europe has further been classified as France, Germany, Spain, the UK, Italy, and the rest of Western Europe. 


The dysmenorrhea treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.


The dysmenorrhea treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.


Key Players


Sanofi (France), GlaxoSmithKline (UK), Bayer AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Focus Consumer Healthcare (US), Johnson & Johnson Inc. (US), Mylan NV (US), Novartis AG (Switzerland), Pfizer, Inc. (US), and Reckitt Benkiser (UK) are some of the key players in the Global Dysmenorrhea Treatment Market.


Regional Market Summary


Global Dysmenorrhea Treatment Market Share (%), by Region, 2018  Dysmenorrhea Treatment Market


Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, and Annual Reports


Geographically, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market in the Americas is anticipated to dominate the global dysmenorrhea treatment market owing to the high prevalence of dysmenorrhea among the population.


Europe is expected to hold the second-largest position in the global dysmenorrhea treatment market. The presence of a large patient population, along with the increasing awareness about the severity of dysmenorrhea, drives the market growth in this region.


Asia-Pacific is expected to be the fastest-growing regional market owing to the growing number of initiatives taken by the government and non-government organizations to create awareness regarding immunization programs and high prevalence rate of infectious diseases.


The market in the Middle East & Africa holds the least share of the market.


Global Dysmenorrhea Treatment Market, by Type



  • Primary Dysmenorrhea

  • Secondary Dysmenorrhea


Global Dysmenorrhea Treatment Market, by Type of Treatment



  • Pain Relievers

  • Hormonal Therapy

  • Surgery


Global Dysmenorrhea Treatment Market, by End User



  • Hospitals and Clinics

  • Research Centers

  • Others


Global Dysmenorrhea Treatment Market, by Region



  • Americas

    • North America

      • US

      • Canada



    • Latin America





  • Europe

    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe



    • Eastern Europe





  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific





  • Middle East & Africa

    • Middle East

    • Africa




Intended Audience



  • Biotechnology Companies

  • Pharmaceutical Companies

  • Hospitals and Clinics

  • Ambulatory Surgical Centers

  • Academic Institutes



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2018: USD 7,450 Million
  • 2027: Significant Value
  •   CAGR   12% (2019-2025)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Type, Type of Treatment and End User
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Sanofi (France), GlaxoSmithKline (UK), Bayer AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Focus Consumer Healthcare (US), Johnson & Johnson Inc. (US), Mylan NV (US), Novartis AG (Switzerland), Pfizer, Inc. (US), and Reckitt Benkiser (UK)
      Key Market Opportunities   probable side effects of the drugs
      Key Market Drivers

  • growing prevalence of dysmenorrhea
  • increasing awareness and concern regarding the severity and therapeutics


  • Frequently Asked Questions (FAQ) :


    Dysmenorrhea treatment market valuation was USD 7450 million in 2018.

    Dysmenorrhea treatment market CAGR would be 12% during the forecast period.

    Side-effects of drugs could restrict the dysmenorrhea treatment market growth.

    The types included in the dysmenorrhea treatment market report are primary dysmenorrhea and secondary dysmenorrhea.

    The dysmenorrhea treatment market would be driven by the Americas.

    Sanofi, Johnson & Johnson Inc., Mylan NV, GlaxoSmithKline, Novartis AG, Reckitt Benckiser, Bayer AG, Focus Consumer Healthcare, Pfizer, Inc., and F. Hoffmann-La Roche Ltd are prime players of the global dysmenorrhea treatment market.